PDF下载 ( 1644 KB)
A clinical study of pulmonary function changes in patients with nonalcoholic fatty liver disease
-
摘要:
目的分析探讨非酒精性脂肪性肝病（NAFLD）患者肺功能的变化及意义。方法选取2016年9月-2017年5月于陆军军医大学大坪医院体检中心进行体检的非酒精性脂肪性肝病（NAFLD）患者为NAFLD组（n=275）,非NAFLD患者为对照组（n=276）,对2组人群的肺功能资料进行分析,包括用力肺活量（FVC）、1秒钟用力呼气容积（FEV1）及FEV1/FVC比值,同时对ALT升高的NAFLD组和ALT正常的NAFLD组的肺功能指标进行比较。计量资料方差齐者2组间比较采用两独立样本t检验,方差不齐则采用非参数Wilcoxon秩和检验。计数资料2组间比较采用χ2检验。结果 NAFLD组FVC、FEV1分别为（3.60±0.87）L、（2.97±0.79）L,均低于对照组的（3.87±0.80）L、（3.17±0.81）L,差异均有统计学意义（t值分别为-3.78、-2.87,P值均<0.01）。nafld组fev1 p="">0.05）。ALT升高的NAFLD组FVC、FEV1、FEV...
Abstract:Objective To investigate the pulmonary function changes in patients with nonalcoholic fatty liver disease (NAFLD) and their clinical significance.Methods A total of 275 NAFLD patients who underwent physical examination in Physical Examination Center of Daping Hospital, Army Medical University, from September 2016 to May 2017 were enrolled as NAFLD group, and 276 non-NAFLD patients were enrolled as control group.Pulmonary function data were analyzed for both groups, including forced vital capacity (FVC) , forced expiratory volume in the first second (FEV1) , and FEV1/FVC ratio, and pulmonary function parameters were compared between NAFLD patients with elevated alanine aminotransferase (ALT) and those with normal ALT.The two-independent-samples t test was used for comparison of continuous data with homogeneity of variance between groups, and the non-parametric Wilcoxon rank-sum test was used for comparison of continuous data with heterogeneity of variance between groups.The chi-square test was used for comparison of categorical data between groups.Results Compared with the control group, the NAFLD group had significantly lower FVC (3.60 ± 0.87 L vs 3.87 ± 0.80 L, t =-3.78, P < 0.01) and FEV1 (2.97 ± 0.79 L vs 3.17 ± 0.82 L, t =-2.87, P < 0.01) .The NAFLD group had a slightly lower FEV1/FVC ratio than the control group (82.06% + 13.88% vs 82.88% ± 13.0%, P > 0.05) .Compared with those with normal ALT, the NAFLD patients with elevated ALT had lower FVC (3.53 ± 0.82 L vs 3.69 ± 0.92 L, P > 0.05) , FEV1 (2.72 ± 0.80 L vs 3.06 ± 0.79 L, P > 0.05) , and FEV1/FVC ratio (81.21% ± 13.00% vs 82.69% ± 12.92%, P > 0.05) .Conclusion NAFLD patients may have pulmonary function damage, which may be associated with metabolic disorder and liver inflammation.
-
Key words:
- non-alcoholic fatty liver disease /
- hepatitis /
- respiratory function tests
-
[1]TAPPER EB, LOOMBA R.NAFLD, Metabolic syndrome, and the fight that will define clinical practice for a generation of hepatologists[J].Hepatology, 2017.[Epub ahead of print] [2]TARGHER G, BYRNE CD, LONARDO A, et al.Non-alcoholic fatty liver disease and risk of incident cardiovascular disease:a meta-analysis[J].J Hepatol, 2016, 65 (3) :589-600. [3]FAN JG, KIM SU, WONG VW.New trends on obesity and NAFLD in Asia[J].J Hepatol, 2017, 67 (4) :862-873. [4]BYRNE CD, TARGHER G.NAFLD:a multisystem disease[J].J Hepatol, 2015, 62 (Suppl 1) :s47-s64. [5]SINN DH, KANG D, CHANG Y, et al.Non-alcoholic fatty liver disease and progression of coronary artery calcium score:a retrospective cohort study[J].Gut, 2017, 66 (2) :323-329. [6]TARGHER G, CHONCHOL M, ZOPPINI G, et al.Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease:is there a link?[J].J Hepatol, 2011, 54 (5) :1020-1029. [7]ZOPPINI G, FEDELI U, GENNARO N, et al.Mortality from chronic liver diseases in diabetes[J].Am J Gastroenterol, 2014, 109 (7) :1020-1025. [8]Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association.Guidelines for management of non-alcoholic fatty liver disease[J].J Clin Hepatol, 2010, 26 (2) :120-124. (in Chinese) 中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].临床肝胆病杂志, 2010, 26 (2) :120-124. [9]LIU YF, XIE W.Progress in treatment of nonalcoholic fatty liver disease[J/CD].Chin J Liver Dis:Electronic Edititon, 2016, 8 (1) :26-28. (in Chinese) 刘玉凤, 谢雯.非酒精性脂肪性肝病治疗进展[J/CD].中国肝脏病杂志:电子版, 2016, 8 (1) :26-28. [10]LIU Y, YANG LQ.Analysis of the prevalence of nonalcoholic fatty liver disease and its related diseases among faculties in a certain university in Beijing[J].China Med Herald, 2017, 32 (14) :178-181. (in Chinese) 刘英, 杨立强.北京某高校教职工非酒精性脂肪性肝病的患病率及相关疾病分析[J].中国医药导报, 2017, 32 (14) :178-181. [11]YOUNG RP, HOPKINS RJ, MARSLAND B.The Gut-liver-lung axis.modulation of the innate immune response and its possible role in chronic obstructive pulmonary disease[J].Am J Respir Cell Mol Biol, 2016, 54 (2) :161-169. [12]du PLESSIS J, van PELT J, KORF H, et al.Association of adipose tissue inflammation with histologic severity of nonalcoholic fatty liver disease[J].Gastroenterology, 2015, 149 (3) :635-648. [13]MEKOV E, SLAVOVA Y, TSAKOVA A, et al.Metabolic syndrome in hospitalized patients with chronic obstructive pulmonary disease[J].Peer J, 2015, 3:e1068. [14]XU C, WAN X, XU L, et al.Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia:one stone hits two birds[J].J Hepatol, 2015, 62 (6) :1412-1419. [15]HIRSOVA P, IBRAHIM SH, KRISHNAN A, et al.Lipid-induced signaling causes release of inflammatory extracellular vesicles from hepatocytes[J].Gastroenterology, 2016, 150 (4) :956-967. [16]BARB D, PORTILLO-SANCHEZ P, CUSI K.Pharmacological management of nonalcoholic fatty liver disease[J].Metabolism, 2016, 65 (8) :1183-1195. [17]BAFFI CW, WOOD L, WINNICA D, et al.Metabolic syndrome and the lung[J].Chest, 2016, 149 (6) :1525-1534. [18]PENG TC, KAO TW, WU LW, et al.Association between pulmonary function and nonalcoholic fatty liver disease in the NHANES III study[J].Medicine (Baltimore) , 2015, 94 (21) :e907. [19]KIM SK, BAE JC, BAEK JH, et al.Decline in lung function rather than baseline lung function is associated with the development of metabolic syndrome:a six-year longitudinal study[J].PLo S One, 2017, 12 (3) :e174228. [20]DA SP, de MELLO MT, CHEIK NC, et al.Interdisciplinary therapy improves biomarkers profile and lung function in asthmatic obese adolescents[J].Pediatr Pulmonol, 2012, 47 (1) :8-17. [21]JUNG DH, SHIM JY, LEE HR, et al.Relationship between nonalcoholic fatty liver disease and pulmonary function[J].Intern Med J, 2012, 42 (5) :541-546. 期刊类型引用(8)
1. 张欣，徐怡琼，罗艳，张富军. 吲哚菁绿清除实验的临床应用及研究进展. 上海医学. 2024(05): 314-317 . 
百度学术2. 李文惠. 分析乳果糖预防肝硬化患者上消化道出血后诱发肝性脑病的疗效. 医学食疗与健康. 2022(13): 29-31+42 . 百度学术3. 吴敏，张丽霞. 肠道微生物代谢组学检测在疾病诊疗中的研究进展. 淮海医药. 2022(04): 434-437 . 百度学术4. 柴晓哲，朱霞峰，王少峰，骆成林. 白蛋白-胆红素评分联合血氨检测对原发性肝癌切除术后并发肝性脑病的预测价值. 肝脏. 2022(09): 994-998 . 百度学术5. 冯其柱，王思雨，张超. 吲哚菁绿荧光显影在困难胆囊腹腔镜胆囊切除术中的应用价值. 临床肝胆病杂志. 2022(11): 2537-2541 . 
本站查看6. 史俪璐，徐慧，陈慧. 双歧杆菌三联活菌胶囊联合乳果糖对经颈静脉肝内门体分流术后肝性脑病的预防效果分析. 中国医学前沿杂志(电子版). 2021(05): 79-83 . 百度学术7. 袁巍，李龙鹤，韩晓玉，刘俊，李波，武金才. TIPS术后发生肝性脑病的临床预测模型建立与效能分析. 现代消化及介入诊疗. 2021(07): 874-877 . 百度学术8. 路志伟. MRI+多层螺旋CT对于肝性脑病患者诊断准确率的影响分析. 中国实用医药. 2021(26): 21-23 . 百度学术其他类型引用(0)
-
百度学术
下载:
